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Direct oral anticoagulants are now commonplace, and reversal agents are recently becoming 
available. Andexanet alfa (AnXa), approved by the United States Food and Drug Administration in 
2018, is a novel decoy molecule that reverses factor Xa inhibitors in patients with major hemorrhage. 
We present a case of a 70-year-old man taking rivaroxaban with hemodynamic instability from 
a ruptured abdominal aortic aneurysm. He received AnXa prior to endovascular surgery, and 
intraoperatively he could not be heparinized for graft placement. Consideration should be given 
to the risks and benefits of AnXa administration in patients who require anticoagulation after 
hemorrhage has been controlled. [Clin Pract Cases Emerg Med. 2019;3(4):390–394.]
INTRODUCTION
Apixaban and rivaroxaban are direct oral anticoagulants 
(DOAC) that inhibit factor Xa (FXa), thereby preventing 
the conversion of prothrombin to thrombin and inducing 
coagulopathy.1 Based on clinical trials that led to United 
States Food and Drug Administration (FDA) approval as 
well as post-marketing experience, DOACs carry a similar 
risk of life-threatening hemorrhage as compared to vitamin 
K antagonists such as warfarin.2-5 Agents for reversal of 
DOAC-induced coagulopathy have only recently been 
developed. Andexanet alfa (AnXa) was reported by Lu et 
al. in 2013 to be a reversal agent for the FXa inhibitors. It 
is a decoy FXa molecule that avidly binds FXa inhibitors, 
temporarily inhibiting their anticoagulant effects.6 It was 
also noted in vitro to have a binding affinity for heparin-
bound antithrombin, thereby suggesting an effect against 
heparin-induced coagulopathy.6-8 
AnXa was approved by the FDA in May 2018 
under regulations allowing for Accelerated Approval 
for Biological Products for Serious or Life-Threatening 
Illnesses (21 CFR 601 Subpart E).9 Approval was based 
on efficacy and safety data from the “Andexanet Alfa, 
a Novel Antidote to the Anticoagulation Effects of FXa 
Inhibitors Apixaban and Rivaroxaban” (ANNEXA-A and 
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-R, respectively) trials in healthy volunteers, as well as 
from preliminary data from the “Andexanet Alfa, a Novel 
Antidote to the Anticoagulation Effects of Factor Xa 
Inhibitors” (ANNEXA-4 ) trial in patients with “acute major 
bleeding.” ANNEXA-4 showed that AnXa has a marked, 
albeit transient, impact on the surrogate outcome of median 
anti-FXa activity among those on apixaban or rivaroxaban 
who have clinically significant hemorrhage.10,11 Notably, 
ANNEXA-4 excluded patients requiring emergent surgery, 
and identified a 10% 30-day risk of thromboembolic 
events.11 Following FDA approval, guidelines have been 
published recommending AnXa for the reversal of apixaban 
and rivaroxaban in patients with major hemorrhage, 
including those who require emergent surgery.12,13 
A ruptured abdominal aortic aneurysm (AAA) is a rare 
but rapidly life-threatening illness, accounting for 6274 U.S 
deaths in 2017.14 Survival depends on early identification, 
effective resuscitation, and rapid access to vascular 
surgery (VS). Increasingly, ruptured aneurysms are being 
managed endovascularly.15 Somewhat counterintuitively, 
to reduce thrombotic complications these patients receive 
intraoperative heparinization once proximal control and 
hemostasis have been achieved.16 For patients taking 
a DOAC with a ruptured aneurysm, initial emergency 
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What do we already know about this clinical 
entity? 
Andexanet alfa is a reversal agent for direct 
Factor Xa inhibitors. It may be valuable in 
patients with major hemorrhage requiring 
operative intervention. 
What makes this presentation of disease 
reportable? 
A patient on rivaroxaban with a ruptured 
aortic aneurysm received andexanet alfa. 
This complicated his emergent aortic repair 
by inhibiting necessary heparinization.
What is the major learning point? 
Patients requiring endovascular surgery 
require careful consideration prior to 
administration of andexanet alfa. 
How might this improve emergency 
medicine practice? 
Increased communication with vascular 
surgeons regarding the use of andexanet alfa 
in endovascular candidates may help prevent 
operative complications.
department (ED) resuscitation may include reversal 
of anticoagulation. These decisions should be made in 
consultation with VS and should consider factors such 
as hemodynamic stability, concern for ongoing bleeding, 
and time to obtaining proximal control. It is unclear 
how treatment with AnXa would impact intraoperative 
anticoagulation and subsequent thrombotic risk.
CASE REPORT
A 70-year-old, 85-kilogram (kg) man with a 
history of atrial fibrillation on rivaroxaban, a known 
4.5 centimeter (cm) infrarenal AAA, and remote three-
vessel coronary artery bypass graft was transferred to 
our academic, tertiary referral center from a community 
hospital with the diagnosis of a ruptured AAA. He had 
last taken 20 milligrams (mg) of rivaroxaban the morning 
of presentation. At 2 pm, he developed abdominal pain 
associated with intermittent ripping sensations into his 
back. He presented to the outside hospital somnolent, 
with a systolic blood pressure of 80 millimeters of 
mercury (mmHg). Computed tomography with angiogram 
demonstrated rupture of his AAA with an associated 
retroperitoneal hematoma. He received two units (U) of 
packed red blood cells (pRBC) prior to transfer. 
The patient arrived in our ED at 9:35 pm, appearing ashen 
and uncomfortable. He had a new oxygen requirement of four 
liters (L) by nasal cannula, a respiratory rate of 24 breaths per 
minute, a heart rate of 103 beats per minute, and a blood pressure 
of 122/85 mmHg. The VS team was emergently consulted and 
he was taken to the operating room (OR) for endovascular aortic 
repair (EVAR) at 10:57 pm. In our ED, laboratory studies showed 
the following: hemoglobin 13.0 grams per deciliter (g/dL) (13.7-
17.5g/dL), creatinine 1.1 mg/dL (0.5-1.2mg/dL), international 
normalized ratio (INR) 2.6 (0.9-1.1), and partial thromboplastin 
time 28.0 seconds (s) (25.0-36.5 s). 
Due to his hypotension at the outside hospital, poor skin 
perfusion, supplemental oxygen requirement, and history 
of recent rivaroxaban dose with elevated INR qualitatively 
suggesting coagulopathy and ongoing bleeding, the patient 
was ordered for  low- dose AnXa (400 mg intravenous bolus 
followed by 4 mg/minute infusion) in consultation with 
VS. Due to the long preparation time, the AnXa was not 
immediately available in the ED, and it was started at 11:07 
pm by the anesthesiologist in the OR. Two additional units 
of pRBCs were administered at 11:30 pm and 11:44 pm in the 
setting of persistent tachycardia to the 120s. A timeline of the 
operative course is outlined in Figure 1.
Intraoperative heparinization (typically 80-100 U/
kg) is used to reduce thromboembolic risk during EVAR.16 
Intensity of anticoagulation is monitored by activated 
clotting time (ACT), with target values greater than 250 
seconds  This patient’s initial ACT by point-of-care assay 
was 135 at 11:48 pm, approximately 40 minutes after the 
AnXa bolus and two-hour infusion was started (non-
coagulopathic range 80-120 s). After obtaining hemostasis, 
the VS team proceeded with anticoagulation. The patient was 
bolused with unfractionated heparin (UFH) 8000 U between 
11:49 pm and 12:04 am, and a repeat ACT at 12:06 am was 
minimally changed (144 seconds). Over the next hour an 
additional 6000 U UFH were given, and the ACT remained 
well below the 250-second goal. The hematology service 
was consulted intraoperatively and recommended transfusing 
a unit of fresh frozen plasma, which was administered at 
1:19 am. For the remainder of the surgery, which ended at 
1:46 am, the ACT never exceeded 152 seconds. 
The VS team continued with aortic graft deployment 
despite subtherapeutic heparinization. The aneurysm extended 
into the right common iliac artery; therefore, to obtain 
adequate endovascular seal and exclusion of the aneurysm, 
the endograft’s right limb was extended into the right external 
iliac artery necessitating coverage of the right hypogastric 
artery. The left iliac limb terminated just proximal to the 
left hypogastric artery. Completion angiogram following 
Clinical Practice and Cases in Emergency Medicine 392 Volume III, no. 4: November 2019
Difficult Intraoperative Heparinization Following Andexanet Alfa Administration Watson et al.
deployment revealed adequate exclusion of the aneurysm; 
however, there was evidence of thrombus in the iliac system 
including the left hypogastric artery.
Following repair, the patient was admitted to the 
surgical intensive care unit, where he was monitored for 
four days. He was discharged with no clinical ischemic 
complications despite extensive thrombosis of his pelvic 
vasculature. Interestingly, the patient’s INR remained 
persistently elevated (1.7–2.1) for the remainder of his 
hospitalization despite remaining off rivaroxaban. The 
hematology service ordered a mixing study and factor VII 
(FVII) concentration, which was low at 21% (normal 65-
180%), suggesting a congenital FVII deficiency. He was 
discharged on rivaroxaban 20 mg daily. At hematology 
clinic follow-up, the patient was well, and his outpatient 
FVII level remained low (18%) and INR remained high 
(3.3). This is consistent with congenital FVII deficiency. 
It is unlikely that the FVII deficiency played a role in 
the subtherapeutic intraoperative heparinization, as FVII 
deficiency is a coagulopathy and affects a different point 
within the coagulation cascade.
DISCUSSION
We have presented the case of a 70-year-old man on 
rivaroxaban who suffered a ruptured AAA, received AnXa 
to reverse FXa inhibitor-induced coagulopathy, and during 
EVAR was difficult to anticoagulate, thus putting him at 
increased post-operative thrombotic risk. He sustained 
thrombosis of his pelvic vasculature without any clinical 
adverse consequences. This case is highly clinically relevant 
given the novelty of both the agent and the intraoperative 
complications at hand; in fact, this case is being published 
within the clinical pharmacy literature as well with a focus 
on the pharmacology of the heparin-AnXa interaction and the 
valuable role of pharmacists in making decisions regarding 
reversal of anticoagulation.17 
This case highlights emerging considerations regarding 
the use of AnXa. This patient underwent an endovascular 
procedure, the safety profile of which is dependent 
on intraoperative heparinization. While in vitro data 
demonstrates inhibition of heparin by AnXa, this relationship 
has not been clinically studied and is not widely known. 
AnXa reversibly binds to the heparin-antithrombin complex, 
rendering heparin ineffective. Therefore, when surgical 
control of hemorrhage is rapidly available, and intraoperative 
anticoagulation is important, administration of AnXa may 
not be warranted.  Emergency physicians (EP) should engage 
their surgical consultants to discuss risks and benefits of 
using this reversal agent preoperatively. 
However, if the EP is caring for a similar patient in 
a facility without definitive surgical capabilities, AnXa 
administration may still be a valuable part of the initial 
resuscitative bundle prior to transfer to a referral center. 
Currently, AnXa is not widely available in all hospitals, but 
Figure 1. Timeline in operating room. Boxes represent administration of medications and blood products, as well as timing of the 
surgical procedure. The solid line represents the measured activated clotting time, which never became therapeutic (dashed line).
ACT, activated clotting time; AnXa, Andexanet alfa; K, thousand; U, units; UFH, unfractionated heparin; pRBC, packed red blood cells; 
FFP, fresh frozen plasma; EVAR, endovascular repair.
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this is expected to change as manufacturing and distribution 
improves. AnXa would normalize coagulation parameters 
during the highest risk period of interfacility transport, while 
its short half-life would allow it to clear by the time the 
patient arrives at the referral center. The ANNEXA-A, -R, 
and -4 studies demonstrated a relative return to expected pre-
AnXa anti-FXa activity four hours post-bolus. Ideally, this 
decision should be made collaboratively between the ED and 
surgical teams. Notably, if a clinician is faced with needing 
to anticoagulate a patient after AnXa is administered, a 
potential strategy would be to use a direct thrombin inhibitor 
(argatroban or bivalirudin), as the therapeutic effect would 
be downstream of AnXa in the coagulation cascade. If a 
patient receives AnXa, it is critical to inform the surgical 
team, so that they can plan on using one of these alternative 
agents for intraoperative anticoagulation.
Based on ANNEXA-4, 10% of patients administered 
AnXa suffered from a thromboembolic event within 30 
days of administration.11 This is somewhat comparable 
to the venous thromboembolism rate of 5-7% from other 
anticoagulant reversal strategies such as prothrombin 
complex concentrates. Patients requiring surgery with a 
baseline thrombotic risk creates a difficult decision for the 
EP regarding the use of any reversal agent. 
Ultimately, AnXa is a valuable intervention for the 
reversal of major hemorrhage in the setting of FXa inhibitor 
use. Less is understood about the role of AnXa in patients 
with aortic catastrophe for whom definitive management 
requires surgery with intraoperative heparinization, and 
for whom there already exists an intra- and postoperative 
thrombotic risk. Based on this case, the decision to use 
AnXa should be made with collaboration between the ED, 
VS, and pharmacy teams, and should take into consideration 
the patient’s acute instability, time to surgical control of the 
aorta, inability to heparinize in the presence of AnXa, and 
the baseline operative thrombotic risk. 
CONCLUSION
We present a case of a 70-year-old man taking 
rivaroxaban who suffered a ruptured AAA and received 
AnXa for stabilization of retroperitoneal hemorrhage, but 
then could not be adequately heparinized during EVAR. 
Although it is has been established that AnXa will prevent 
anticoagulation with heparin, this is not well known within the 
clinical community. Patients who require heparinization for 
endovascular surgery may not be appropriate for immediate 
preoperative AnXa administration. 
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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